Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO.

Biotechnology

Outlook Therapeutics

Outlook Therapeutics' headquarters in Woodbridge Township, NJ, United States

Lawrence A. Kenyon

Terry Dagnon

Jennifer Kissner

Surendra Sharma

Dan Courtney

Alison Oliver

Sharyn C.

Markus Muehlemann

Joseph Manhede CA, CPA, MBA

Elaine Ludovico (Sirmans)

Christopher Yonan

Jedd Comiskey

Lauren Nelson

Entisar Dahan, MPM, PHR

Danielle Greene

Kathleen Billman

Kolleen Fitzgerald

Pamela Monterola

George Bitar

Tony Moses

Gerd Auffarth

Andong Huang

Randy Thurman

Faisal G. Sukhtian

Kurt J. Hilzinger

Julian Gangolli

Yezan Haddadin

The Directors team at Outlook Therapeutics encompasses a range of specialized leaders responsible for overseeing critical functions such as human resources, patient access and marketing, bioassay development, clinical affairs, physician relations, and financial planning and analysis. This team ensures strategic alignment and operational efficiency across various departments to support the clinical development and potential FDA approval of ONS-5010 / LYTENAVA™ (bevacizumab-vikg).

Directors

The Operations Team at Outlook Therapeutics is responsible for ensuring the seamless production, compliance, and delivery of ONS-5010 / LYTENAVA™ (bevacizumab-vikg). This includes overseeing manufacturing processes, supply chain management, quality assurance, and commercial operations to support the successful development and market introduction of the ophthalmic formulation for retinal diseases.

Operations Team

The Leadership Team at Outlook Therapeutics is responsible for guiding the strategic direction of the company, overseeing the development and commercialization of ONS-5010 / LYTENAVA™. Comprising key executives such as the President & CEO, Chief Commercial Officer, CFO, and COO, this team collaborates to ensure operational excellence, drive financial growth, and navigate regulatory pathways to bring innovative treatments for retinal diseases to market.

Leadership Team

The Vice Presidents team at Outlook Therapeutics is responsible for high-level strategic oversight and decision-making across critical domains. This includes identifying and securing licensing opportunities and managing mergers and acquisitions (Senior Vice President, Licensing and Mergers & Acquisitions), overseeing clinical trials and ensuring regulatory compliance (Senior Vice President, Clinical & Regulatory Affairs), and guiding medical strategies and stakeholder engagement relating to ONS-5010 / LYTENAVA™ (Senior Vice President, Medical Affairs).

Vice Presidents

Outlook Therapeutics

Org chart

Board & advisors

Teams

Directors

Operations Team

Leadership Team

Vice Presidents

Offices

Outlook Therapeutics

Org chart

Board & advisors

Teams

Directors

Operations Team

Leadership Team

Vice Presidents

Offices

Related companies